{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:48Z","timestamp":1790674128678,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,6,15]],"date-time":"2009-06-15T00:00:00Z","timestamp":1245024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Transfusion\u2010transmitted viral infection (TTI) is a major problem in patients receiving blood products. Monitoring high\u2010risk patients is essential for assessing the epidemiology of blood\u2010borne infections.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> A 1\u2010year, cross\u2010sectional seroprevalence study in patients with a history of multiple transfusions was conducted. Peripheral blood samples were titered to detect serologic markers of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). The presence of these viruses and demographic, behavioral, and medical traits were assessed.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> A total of 300 male and female multiply transfused patients with a mean age of 30.7 (\u00b117.5) years were studied. The prevalence was 13.7% for HCV, 7% for HBV, and 1.7% for HIV. Patients with hemophilia had the highest prevalence for HCV and HIV infections, and hemodialyzed patients, for HBV infection. The risk factors related to acquired HCV were hemophilia (odds ratio [OR], 5.6; 95% confidence interval [CI], 2.5\u201012.6), more than five hospitalizations (OR, 3.8; 95% CI, 1.6\u20108.9), and having received a transfusion before mandatory screening in 1993 (OR, 8.4; 95% CI, 2.0\u201034.6), and for HIV, having received a transfusion before 1987 (OR, 19.0; 95% CI, 2.0\u2010177.7). The main risk factors for HBV were having end\u2010stage renal disease and being treated with hemodialysis (OR, 3.7; 95% CI, 1.4\u20109.9) and transplantation (OR, 4.2; 95% CI, 1.4\u201012.1).<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> This study showed that HCV infection was more frequently identified than HBV and HIV infections in multiply transfused Mexican patients. Additionally, several risk factors are associated with TTI such as mandatory screenings before 1987 and 1993, which were the most important for HIV and HCV infections but not for HBV.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2009.02248.x","type":"journal-article","created":{"date-parts":[[2009,6,15]],"date-time":"2009-06-15T17:51:25Z","timestamp":1245088285000},"page":"2200-2207","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico"],"prefix":"10.1111","volume":"49","author":[{"given":"Gloria M.","family":"Calder\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Gonz\u00e1lez\u2010Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar R.","family":"Gonz\u00e1lez\u2010Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"Novelo\u2010Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.","family":"Terrazas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Mart\u00ednez\u2010Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia R.","family":"Cort\u00e9s\u2010M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Blanco\u2010Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Rodr\u00edguez\u2010Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Cort\u00e9s\u2010G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Guadalupe","family":"Mej\u00eda\u2010Bocanegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.5.541"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1246-7820(02)00276-8"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2006.04.007"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-922224"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/47.4.239"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0036-46651993000300008"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0401.980102"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.1.12-29.2005"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05702.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.8.959"},{"key":"e_1_2_8_12_2","first-page":"495","article-title":"Pathogen reduction technology: methods, status of clinical trials, and future prospects","volume":"2","author":"Corash L","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2006.07.007"},{"key":"e_1_2_8_14_2","volume-title":"Norma Oficial Mexicana NOM\u2010003\u2010SSA2\u20101993 para la disposici\u00f3n de sangre humana y sus componentes con fines terape\u00faticos","year":"1993"},{"key":"e_1_2_8_15_2","volume-title":"Modificaci\u00f3n a la norma Oficial Mexicana NOM\u2010010\u2010SSA2\u20101993, para la Prevenci\u00f3n y Control de la Infecci\u00f3n por Virus de la Inmunodeficiencia Humana","year":"1993"},{"key":"e_1_2_8_16_2","first-page":"556","article-title":"The epidemiology of AIDS\/HIV in Mexico: from 1983 to March 1995","volume":"37","author":"Valdespino\u2010G\u00f3mez JL","year":"1995","journal-title":"Salud Publica Mex"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200212003-00003"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0188-4409(01)00350-2"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646204323012841"},{"key":"e_1_2_8_20_2","first-page":"246","article-title":"Hepatitis C viral in patients with terminal chronic kidney failure. I. Prevalence","volume":"52","author":"Gonzalez\u2010Michaca L","year":"2000","journal-title":"G Rev Invest Clin"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.9.4321-4322.2004"},{"key":"e_1_2_8_22_2","first-page":"657","article-title":"Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors","volume":"140","author":"Rivera\u2010Lopez MR","year":"2004","journal-title":"Gac Med Mex"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(05)80030-7"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(05)80031-9"},{"key":"e_1_2_8_25_2","first-page":"256","article-title":"The prevalence of viral hepatitis and HIV infections in patients with congenital bleeding disorders","volume":"101","author":"Jubelirer SJ","year":"2005","journal-title":"W V Med J"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(20000201)63:2<103::AID-JMV1003>3.0.CO;2-E"},{"key":"e_1_2_8_27_2","first-page":"1584","article-title":"End\u2010stage liver disease in persons with hemophilia and transfusion\u2010associated infections","volume":"100","author":"Goedert JJ","year":"2002","journal-title":"Blood"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530370033027"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310329"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2006.08.003"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199802000-00021"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00811.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.03.031"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.3.429"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.4103\/0255-0857.13872"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-006-0162-7"},{"key":"e_1_2_8_37_2","first-page":"1200","article-title":"Hepatitis C virus infection in a hematology ward: evidence for nosocomial transmission and impact on hematologic disease outcome","volume":"87","author":"Silini E","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_8_38_2","first-page":"1","article-title":"Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention","volume":"52","author":"Alter MJ","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01886.x"},{"key":"e_1_2_8_40_2","first-page":"101","article-title":"Safety of the blood supply in Mexico from 1999 to 2003","volume":"58","author":"Vazquez\u2010Flores JA","year":"2006","journal-title":"Rev Invest Clin"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2009.02248.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2009.02248.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T18:02:25Z","timestamp":1695924145000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2009.02248.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1537-2995.2009.02248.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2009.02248.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}